Desirudin

Desirudin is a recombinant, purified form of the naturally occurring anticoagulant protein hirudin, which is isolated from the saliva of the medicinal leech. It is a direct thrombin inhibitor that is used clinically in the treatment of acute thromboembolic conditions such as deep vein thrombosis and pulmonary embolism. The drug is administered intravenously and has a relatively short half‑life of approximately 15 to 20 minutes, which allows for rapid titration and easy reversal in case of bleeding complications.

The pharmacological action of desirudin involves binding to both the active site and exosite I of thrombin, thereby preventing the conversion of fibrinogen to fibrin and inhibiting platelet aggregation. Its high affinity for thrombin gives it a potent antithrombotic effect without the need for systemic anticoagulation, which may reduce the risk of hemorrhagic events compared to conventional agents such as heparin or warfarin. Because it does not bind to plasma proteins, it requires close monitoring of coagulation parameters including activated partial thromboplastin time (aPTT) and thrombin time (TT).

Side effects are largely associated with bleeding and carry a lower incidence of allergic reactions compared with native hirudin. Minor adverse events frequently reported include mild bruising, transient thrombocytopenia, and dose‐related increases in aPTT. Serious bleeding may occur, especially in patients with hepatic impairment or concomitant anticoagulant therapy. Drug interactions are limited, but concomitant use with other anticoagulants, antiplatelet agents, or NSAIDs may increase bleeding risk.

Desirudin was first developed in the early 1990s through recombinant DNA technology which allowed large‑scale production in bacterial expression systems. The drug was approved by regulatory agencies in a number of countries for the short‑term treatment of certain thromboembolic disorders. Despite its clinical advantages, desirudin has largely been supplanted by newer anticoagulants, particularly the factor Xa inhibitors and direct thrombin inhibitors that are administered orally, owing to the convenience and lower monitoring requirements. However, desirudin remains a valuable option in specific clinical scenarios where rapid onset and fine control of anticoagulant effect are required, such as during percutaneous coronary interventions or in patients with heparin resistance.